Search the GHTC website

Global health R&D delivers for Hawaii

US government investment in global health R&D has delivered

$37.2 million
to Hawaii research institutions
450+ new jobs
for Hawaii
Hawaii's top USG-funded global health R&D institutions

Hawaii's top USG-funded global health R&D institutions

University of Hawaii, Manoa
$30.9 million
Undisclosed HI-based industry recipient
$2.3 million
Hawaii Biotech, Inc.
$2.2 million
University of Hawaii, Hilo
$529 thousand
Kuakini Medical Center
$521 thousand
Panthera Biopharma LLC*
$368 thousand
Hawaii Integrated Analytics
$180 thousand
HNU Photonics LLC
$100 thousand

Hawaii's top areas of global health R&D by USG funding

Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Multi-disease/health area R&D
Bunyaviral diseases (including CCHF, RVF, SFTS)
Reproductive health
Global health R&D at work in Hawaii

Researchers at the University of Hawaii John A. Burns School of Medicine have partnered with Hawaii Biotech and another US-based biotech company to advance research on a thermal stabilization technology to make vaccines heat stable. Most vaccines available today must be continuously refrigerated to remain effective. This can make them challenging to deliver in last-mile settings worldwide that lack reliable electricity and cold chain infrastructure. Using this technology, collaborators have already advanced candidate vaccines for Ebola and COVID-19 that have shown promise in early-stage research. If successful, this thermal stabilization technology holds the potential to improve immunization efforts globally by simplifying the logistics of vaccine storage and administration.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Therese Bjorn Mason